Literature DB >> 9277517

Adenylyl cyclase isoforms and vasopressin enhancement of agonist-stimulated cAMP in vascular smooth muscle cells.

J Zhang1, M Sato, E Duzic, S W Kubalak, S M Lanier, J G Webb.   

Abstract

The influence of arginine vasopressin (AVP) on agonist-stimulated adenosine 3',5'-cyclic monophosphate (cAMP) accumulation was investigated in vascular smooth muscle cells (VSMC) cultured from rat thoracic aorta. Incubation of VSMC with AVP for 60 s produced a 2- to 2.5-fold enhancement of isoproterenol-induced cAMP formation. AVP also increased cAMP stimulation by the prostaglandin I2 analogue iloprost. The effect of AVP to enhance agonist-stimulated cAMP formation was completely inhibited in cells pretreated with a selective antagonist of V1 vasopressin receptors but was not affected by blockade of V2 receptors. Inhibition of protein kinase C activation failed to alter the action of AVP to potentiate cAMP stimulation, but treatment of cells with calmodulin antagonists significantly attenuated this effect of the peptide. Moreover, depletion of Ca2+ stores with thapsigargin decreased AVP enhancement of isoproterenol-stimulated cAMP by > 70%. The action of AVP to increase cAMP stimulation was also demonstrated in freshly isolated strips of rat aorta where treatment with peptide produced a twofold increase in isoproterenol-stimulated cAMP formation. RNA blot analysis indicated expression in VSMC of mRNA encoding type III adenylyl cyclase, a Ca(2+)-calmodulin-sensitive isoform of the effector. Furthermore, when detergent-solubilized membrane extract was subjected to calmodulin affinity chromatography, a peak of adenylyl cyclase activity was identified which had affinity for calmodulin matrix in the presence of Ca2+. The results indicate that AVP activates V1 receptors in VSMC to enhance agonist-stimulated cAMP formation by a Ca(2+)-calmodulin-dependent mechanism and suggest that type III adenylyl cyclase may provide a focal point in the VSMC for cross talk between constrictor and dilator pathways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9277517     DOI: 10.1152/ajpheart.1997.273.2.H971

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Reciprocal regulation of capacitative and non-capacitative Ca2+ entry in A7r5 vascular smooth muscle cells: only the latter operates during receptor activation.

Authors:  Zahid Moneer; Colin W Taylor
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

2.  cAMP/PKA-dependent increases in Ca Sparks, oscillations and SR Ca stores in retinal arteriolar myocytes after exposure to vasopressin.

Authors:  Owen Jeffries; Mary K McGahon; Peter Bankhead; Maria Manfredi Lozano; C Norman Scholfield; Tim M Curtis; J Graham McGeown
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-03       Impact factor: 4.799

3.  Biochemical and molecular aspects of vascular adrenergic regulation of blood pressure in the elderly.

Authors:  William E Schutzer; Scott L Mader
Journal:  Int J Hypertens       Date:  2011-09-22       Impact factor: 2.420

Review 4.  Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

5.  EP2 receptor mediated cAMP release is augmented by PGF 2 alpha activation of the FP receptor via the calcium-calmodulin pathway.

Authors:  A B Abera; K J Sales; R D Catalano; A A Katz; H N Jabbour
Journal:  Cell Signal       Date:  2009-09-25       Impact factor: 4.315

6.  Role of adenylyl cyclase in reduced β-adrenoceptor-mediated vasorelaxation during maturation.

Authors:  O A López-Canales; M C Castillo-Hernandez; H Vargas-Robles; A Rios; J S López-Canales; B Escalante
Journal:  Braz J Med Biol Res       Date:  2016-07-04       Impact factor: 2.590

Review 7.  Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders.

Authors:  Ewa Szczepanska-Sadowska; Katarzyna Czarzasta; Agnieszka Cudnoch-Jedrzejewska
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.